Artiva Biotherapeutics, Inc. (ARTV)
(Delayed Data from NSDQ)
$13.11 USD
-0.85 (-6.09%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $13.00 -0.11 (-0.84%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ARTV 13.11 -0.85(-6.09%)
Will ARTV be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ARTV based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ARTV
Artiva Biotherapeutics appoints Alison Moore, Ph.D., to Its Board of Directors
Artiva Biotherapeutics appoints Alison Moore, Ph.D., to Its Board of Directors
U.S. IPO Weekly Recap: Active IPO Market Continues With KinderCare And Trio Of Biotech Deals
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
Buy Rating Affirmed for Artiva Biotherapeutics on Promising AlloNK Developments and Trial Optimism